Loading...
The approval of raltegravir, the first integrase inhibitor, in 2007 ushered in a new era for managing treatment-experienced patients with HIV infection (JW AIDS Clin Care Oct 22 2007). Clinicians quickly saw that the drug was highly potent, was well tolerated, and greatly enhanced the activity of salvage regimens. For treatment-naive patients, phase II study results for raltegravir were published in 2007, and phase III findings were first presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, in 2008. Now we have the published results of the phase III trial, which was funded by raltegravir's manufacturer.
In all, 566 treatment-naive patients were randomized to receive either once-daily efavirenz or twice-daily ral…